Advertisement
Canada markets open in 2 hours 54 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7265
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    82.41
    -0.32 (-0.39%)
     

  • Bitcoin CAD

    89,006.64
    +4,033.48 (+4.75%)
     

  • CMC Crypto 200

    1,334.22
    +21.60 (+1.67%)
     

  • GOLD FUTURES

    2,396.90
    -1.10 (-0.05%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,427.75
    -119.50 (-0.68%)
     

  • VOLATILITY

    19.23
    +1.23 (+6.83%)
     

  • FTSE

    7,831.88
    -45.17 (-0.57%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6813
    -0.0008 (-0.12%)
     

Array BioPharma (ARRY) Looks Good: Stock Adds 5.9% in Session

Zacks Equity Research
Updated

Array BioPharma Inc. ARRY was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 22.3% in the past one-month time frame.

The company’s Zacks Consensus Estimate for the current quarter has moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Array BioPharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Array BioPharma Inc. Price

Array BioPharma Inc. Price | Array BioPharma Inc. Quote

ADVERTISEMENT

Investors interested in the Medical - Biomedical and Genetics industry may consider Alexion Pharmaceuticals, Inc. ALXN, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ARRY going up? Or down? Predict to see what others think: Up or Down

One Simple Trading Idea

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.

Learn more >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
Array BioPharma Inc. (ARRY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research